EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Yuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, Shuhei Koide, Ola Rizq, Kazumasa Aoyama, Junjie Ao, Tatsuya Kaneko, Hiroaki Kanzaki, Kengo Kanayama, Takahiro Maeda, Tomoko Saito, Ryo Nakagawa, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Sadahisa Ogasawara, Eiichiro Suzuki, Shingo Nakamoto, Shin YasuiRintaro Mikata, Ryosuke Muroyama, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Naoya Mimura, Anqi Ma, Jian Jin, Yoh Zen, Masayuki Otsuka, Atsushi Kaneda, Atsushi Iwama, Naoya Kato

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences